Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Paul Kenny
Icahn School of Medicine at Mount Sinai, Department: Neurosciences
Should you be removed from our database? Contact us at [email protected]. Read more below.
Eolas Therapeutics, Inc.
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Dr. Paul Kenny (the Principal Investigator on this study, Ward-Coleman Professor and Chair of the Dorothy H. and Lewis Rosenstiel Department of Pharmacology and Systems Therapeutics) is a co-founder and equity holder in Eolas Therapeutics, a privately held company that is working to develop compounds to treat nicotine and cocaine addiction.
Dr. Kenny is also a named inventor on a patent relating to Orexin 1 receptor antagonists for addiction.
Nicotinic receptors and alcohol reinforcement
PROJECT NARRATIVE Alcohol and tobacco dependence are leading causes of premature death and disease in the United States. Approximately 80% of alcohol-dependent individuals are also regular tobacco smokers. This suggests that common underlying mechanisms may regulate the motivational properties of alcohol and nicotine, the major addictive component of tobacco smoke. Human genome-wide association studies have revealed that allelic variation in CHRNA5, the gene encoding the ?5 nicotinic acetylcholine receptor (nAChR) subunit located in chromosome region 15q25, increases the risk of developing tobacco and alcohol dependence. Expression of ?5 nAChR subunits is enriched in the medial habenula (MHb)-interpeduncular nucleus (IPN) pathway. Recently, our laboratory established that nAChRs containing ?5 in the MHb-IPN system regulate nicotine intake. Here, we will test the hypothesis that nAChRs containing ?5-containing nAChRs in the MHb-IPN pathway regulate the motivational properties of alcohol. This program of research promises to identify new targets for the development of therapeutic agents for alcohol and tobacco dependence and may therefore have a significant positive impact on human health.
Filed on July 27, 2016.
Tell us what you know about Paul Kenny's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “Paul Kenny”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Paul Kenny | Icahn School of Medicine at Mount Sinai | Conflict of Interest | Eolas Therapeutics | $40,000 - $59,999 |
| Paul Kenny | Icahn School of Medicine at Mount Sinai | Conflict of Interest | Eolas Therapeutics | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.